Show simple item record

dc.contributor.authorOtero-Losada, Matilde
dc.contributor.authorPetrovsky, Nikolai
dc.contributor.authorAlami, Abdallah
dc.contributor.authorCrispo, James A.
dc.contributor.authorMattison, Donald
dc.contributor.authorCapani, Francisco
dc.contributor.authorGoetz, Christopher
dc.contributor.authorKrewski, Daniel
dc.contributor.authorPerez-Lloret, Santiago
dc.date.accessioned2024-04-12T06:27:57Z
dc.date.available2024-04-12T06:27:57Z
dc.date.issued2023
dc.identifier10.1080/14740338.2022.2120607
dc.identifier.issn14740338
dc.identifier.urihttps://hdl.handle.net/20.500.12728/11185
dc.description.abstractBackground: Information on neurological and psychiatric adverse events following immunization (AEFIs) with COVID-19 vaccines is limited. Research design & methods: We examined and compared neurological and psychiatric AEFIS reports related to BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines and recorded in the United Kingdom Medicines and Healthcare products Regulatory Agency between 9 December 2020 and 30 June 2021. Results: As of 30 June 2021, 46.1 million doses of ChAdOx1 and 30.3 million doses of BNT162b2 had been administered. The most frequently reported AEFI was headache with 1,686 and 575 cases per million doses of ChAdOx1 and BNT162b2, respectively. AEFIs more frequently reported after CHAdOx1 compared with BNT162b2 vaccination were Guillain-Barré syndrome (OR, 95% CI = 2.53, 1.82–3.51), freezing (6.66, 3.12–14.22), cluster headache (1.53, 1.28–1.84), migraine (1.23,1.17–1.30), postural dizziness (1.24,1.13–1.37), tremor (2.86, 2.68–3.05), headache (1.40, 1.38–1.43), paresthesia (1.11, 1.06–1.16), delirium (1.85, 1.45–2.36), hallucination (2.20, 1.82–2.66), poor quality sleep (1.53, 1.26–1.85), and nervousness (1.54, 1.26–1.89) Reactions less frequently reported with ChAdOx1 than with BNT162b2 were Bell’s palsy (0.47, 0.41–0.55), anosmia (0.58, 0.47–0.71), facial paralysis (0.35, 0.29–0.41), dysgeusia (0.68, 0.62–0.73), presyncope (0.48, 0.42–0.55), syncope (0.63, 0.58–0.67), and anxiety (0.75 (0.67–0.85). Conclusion: Neurological and psychiatric AEFIs were relatively infrequent, but each vaccine was associated with a distinctive toxic profile. © 2022 Informa UK Limited, trading as Taylor & Francis Group.es_ES
dc.language.isoenes_ES
dc.publisherTaylor and Francis Ltd.es_ES
dc.subjectBNT162b2es_ES
dc.subjectChAdOx1es_ES
dc.subjectCOVID-19es_ES
dc.subjectneurologyes_ES
dc.subjectpharmacovigilancees_ES
dc.subjectpsychiatryes_ES
dc.subjectsafetyes_ES
dc.subjectvaccineses_ES
dc.titleDisproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdomes_ES
dc.typeArticlees_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record